IRIS PubliCatt
PubliCatt è il repository istituzionale ad accesso aperto dell'Università Cattolica del Sacro Cuore, dove gli utenti autorizzati afferenti all'Ateneo provvedono direttamente e autonomamente a depositare e a rendere visibili le proprie pubblicazioni, inserendo i dati descrittivi del documento stesso ("metadati", quali il titolo, autore, abstract, etc.) e, laddove possibile, il testo della pubblicazione stessa (full-text).
PubliCatt utilizza la piattaforma IRIS (Institutional Research Information System) sviluppata da CINECA.
EnglishThere is a continuing need for an immunosuppressive therapy that offers a high benefit-risk profile for renal transplant recipients, supporting long-term patient and graft survival while minimizing cumulative nephrotoxicity and other side effects. Belatacept , the first biological agent developed for primary maintenance immunosuppression, was recently approved for use in Europe. Belatacept combined with corticosteroids and a mycophenolic acid is indicated for prophylaxis of graft rejection in adults receiving renal transplant. Its use is contraindicated in Epstein-Barr virus seronegative or serostatus unknown patients due to increased risk of developing posttransplant lymphoproliferative disorder.
Grinyó, J., Budde, K., Citterio, F., Charpentier, B., Belatacept utilization recommendations: an expert position, <<EXPERT OPINION ON DRUG SAFETY>>, 2013; 12 (1): 111-122. [doi:10.1517/14740338.2013.748747] [http://hdl.handle.net/10807/52125]
| Autori: | ||
| Titolo: | Belatacept utilization recommendations: an expert position | |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1517/14740338.2013.748747 | |
| Data di pubblicazione: | 2013 | |
| Abstract: | There is a continuing need for an immunosuppressive therapy that offers a high benefit-risk profile for renal transplant recipients, supporting long-term patient and graft survival while minimizing cumulative nephrotoxicity and other side effects. Belatacept , the first biological agent developed for primary maintenance immunosuppression, was recently approved for use in Europe. Belatacept combined with corticosteroids and a mycophenolic acid is indicated for prophylaxis of graft rejection in adults receiving renal transplant. Its use is contraindicated in Epstein-Barr virus seronegative or serostatus unknown patients due to increased risk of developing posttransplant lymphoproliferative disorder. | |
| Lingua: | Inglese | |
| Rivista: | ||
| Citazione: | Grinyó, J., Budde, K., Citterio, F., Charpentier, B., Belatacept utilization recommendations: an expert position, <<EXPERT OPINION ON DRUG SAFETY>>, 2013; 12 (1): 111-122. [doi:10.1517/14740338.2013.748747] [http://hdl.handle.net/10807/52125] | |
| Appare nelle tipologie: | Articolo in rivista, Nota a sentenza |
File in questo prodotto:
Copyright © 2022